Substantial Dose Reduction of Lorlatinib, Including Ultra-Low and Intermittent Dosing, in ALK-Positive Advanced NSCLC: A Real-World Analysis (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1021eP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Takako Inoue; Shota Fukuda; Kinnosuke Matsumoto; Tomoko Harima; Soichiro Minami; Nobuaki Mamesaya; Kei Kunimasa; Motohiro Tamiya; Kazumi Nishino
|